Drug Shortage Report for TEVA-GLICLAZIDE
| Report ID | 88164 |
| Drug Identification Number | 02238103 |
| Brand name | TEVA-GLICLAZIDE |
| Common or Proper name | GLICLAZIDE |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | GLICLAZIDE |
| Strength(s) | 80MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 & 500 |
| ATC code | A10BB |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for shortage | Shortage of an active ingredient. |
| Anticipated start date | |
| Actual start date | 2019-07-02 |
| Estimated end date | 2020-07-31 |
| Actual end date | 2020-07-22 |
| Shortage status | Resolved |
| Updated date | 2020-07-23 |
| Company comments | Delays getting API for next lots. Allocating to 100% of our market. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.